Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "extension" : [ {
        "extension" : [ {
          "valueString" : "concept",
          "url" : "path"
        }, {
          "url" : "count",
          "valueInteger" : 11
        } ],
        "url" : "http://health-samurai.io/extensions/excised-data"
      } ]
    } ]
  },
  "date" : "2019-01-08T01:00:08-05:00",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "Oncology Nursing Society Steward",
  "jurisdiction" : [ {
    "coding" : [ {
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    } ]
  } ],
  "purpose" : "(Clinical Focus: This value set contains RxNORM concepts for various checkpoint inhibitor agents, regardless of dosage or administration route.),(Data Element Scope: Various drugs used in the treatment of cancer which may cause fatigue.),(Inclusion Criteria: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab),(Exclusion Criteria: Brand name drugs and drug packs. Chemotherapy and biotherapy agents which may cause fatigue.)",
  "name" : "CheckpointInhibitorsWithPotentialToCauseGrade3OrHigherFatigue",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1657005",
      "display" : "40 ML ipilimumab 5 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1657012",
      "display" : "10 ML ipilimumab 5 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1657190",
      "display" : "4 ML nivolumab 10 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1657195",
      "display" : "10 ML nivolumab 10 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1657746",
      "display" : "pembrolizumab 50 MG Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1657750",
      "display" : "4 ML pembrolizumab 25 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1792780",
      "display" : "20 ML atezolizumab 60 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1875542",
      "display" : "10 ML avelumab 20 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1919507",
      "display" : "2.4 ML durvalumab 50 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1919515",
      "display" : "10 ML durvalumab 50 MG/ML Injection",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1991412",
      "display" : "24 ML nivolumab 10 MG/ML Injection",
      "version" : "04012024"
    } ],
    "total" : 11,
    "identifier" : "urn:uuid:d77725fb-5920-4f61-b8ba-dc4bbf1206a6",
    "timestamp" : "2024-04-23T19:58:31-04:00"
  },
  "title" : "Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue",
  "extension" : [ {
    "valueString" : "Oncology Nursing Society Author",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2022-12-15",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2019-01-08",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "9db538fe-bf82-490a-9c22-bbe49d291a0d",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.2.1006",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.7643.2.1006"
  } ],
  "version" : "20190108"
}